# A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

> **NCT04590326** · PHASE1,PHASE2 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 612 (estimated)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
- Endometrial Cancer

## Interventions

- **DRUG:** REGN5668
- **DRUG:** Cemiplimab
- **DRUG:** Ubamatamab
- **DRUG:** Sarilumab
- **DRUG:** Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]

## Key facts

- **NCT ID:** NCT04590326
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-12-08
- **Primary completion:** 2027-03-25
- **Final completion:** 2027-11-30
- **Target enrollment:** 612 (ESTIMATED)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04590326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04590326, "A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT04590326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*